These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3034139)

  • 1. Prostaglandins, leukotrienes, and platelet-activating factor in shock.
    Feuerstein G; Hallenbeck JM
    Annu Rev Pharmacol Toxicol; 1987; 27():301-13. PubMed ID: 3034139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor and shock.
    Feuerstein G; Siren AL
    Prog Biochem Pharmacol; 1988; 22():181-90. PubMed ID: 3043432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin.
    Greaves MW; Camp RD
    Arch Dermatol Res; 1988; 280 Suppl():S33-41. PubMed ID: 2841909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane A2 and leukotrienes are eicosanoid mediators of shock and ischemic disorders.
    Lefer AM
    Prog Clin Biol Res; 1988; 264():101-14. PubMed ID: 2837782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the release of prostaglandins, thromboxanes, and leukotrienes from anaphylactic lungs by a platelet-activating factor (PAF) antagonist and its stimulation by PAF.
    Sirois P; Harczy M; Braquet P; Borgeat P; Maclouf J; Pradelles P
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17B():1033-7. PubMed ID: 2823554
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure.
    Lefer AM
    Crit Care Clin; 1989 Apr; 5(2):331-52. PubMed ID: 2650821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB; Li CL; Lam MH; Shen TY
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-activating factor and leukotriene biosynthesis in whole blood. A model for the study of transcellular arachidonate metabolism.
    Fradin A; Zirrolli JA; Maclouf J; Vausbinder L; Henson PM; Murphy RC
    J Immunol; 1989 Dec; 143(11):3680-5. PubMed ID: 2555415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.
    Macconi D; Benigni A; Morigi M; Ubiali A; Orisio S; Livio M; Perico N; Bertani T; Remuzzi G; Patrono C
    J Lab Clin Med; 1989 May; 113(5):549-60. PubMed ID: 2541212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cytoskeletal rearrangement by botulinum C2 toxin amplifies ligand-evoked lipid mediator generation in human neutrophils.
    Grimminger F; Sibelius U; Aktories K; Suttorp N; Seeger W
    Mol Pharmacol; 1991 Oct; 40(4):563-71. PubMed ID: 1656192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled PAF stimulates leukotriene and thromboxane A2 production in humans.
    Taylor IK; Ward PS; Taylor GW; Dollery CT; Fuller RW
    J Appl Physiol (1985); 1991 Oct; 71(4):1396-402. PubMed ID: 1661723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoxygenase metabolites modulate vascular-derived platelet activating factor production following endotoxin challenge.
    Corl CM; Contreras GA; Sordillo LM
    Vet Immunol Immunopathol; 2010 Jul; 136(1-2):98-107. PubMed ID: 20359754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil degranulation responses to combinations of arachidonate metabolites and platelet-activating factor.
    O'Flaherty JT; Wykle RL; Thomas MJ; McCall CE
    Res Commun Chem Pathol Pharmacol; 1984 Jan; 43(1):3-23. PubMed ID: 6322256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid metabolism and signal transduction in endothelial cells.
    Whatley RE; Zimmerman GA; McIntyre TM; Prescott SM
    Prog Lipid Res; 1990; 29(1):45-63. PubMed ID: 2128404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of arachidonate metabolites in ocular inflammation.
    Bhattacherjee P
    Prog Clin Biol Res; 1989; 312():211-27. PubMed ID: 2508125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of platelet-activating factor-induced leukotriene synthesis in neutrophils by granulocyte-macrophage colony-stimulating factor (GM-CSF): studies on the mechanism of action of GM-CSF.
    McColl SR; Krump E; McDonald PP; Braquet M; Naccache PH; Borgeat P
    J Lipid Mediat; 1990; 2 Suppl():S119-27. PubMed ID: 1966811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of thromboxane A2, prostacyclin and other eicosanoids in the cardiovascular system.
    Müller B
    Therapie; 1991; 46(3):217-21. PubMed ID: 1792655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of lipid mediators in shock states.
    Lefer AM
    Circ Shock; 1989 Jan; 27(1):3-12. PubMed ID: 2492907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins.
    Giembycz MA; Kroegel C; Barnes PJ
    J Immunol; 1990 May; 144(9):3489-97. PubMed ID: 2158510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-activating factor (PAF) and PAF antagonists in asthma.
    Hosford D; Mencia-Huerta JM; Braquet P
    Crit Rev Ther Drug Carrier Syst; 1990; 7(3):261-73. PubMed ID: 2073689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.